Company profile: uniQure

1.1 - Company Overview

uniQure

Headquarter: The Netherlands

Founded: 20XX🔒

Employees: 100-500🔒

🌐 Website

Company description

Provider of gene-based therapies focused on research and early development. Offerings include AMT-130 for Huntington’s disease, Etranacogene Dezaparvovec for severe or moderately severe Hemophilia B, AMT-260 for refractory temporal lobe epilepsy, AAV-miQURE targeting ALS C9orf72 transcripts, and the linQURE platform for multi-transcript targeting; a leader that developed the first and only EU-approved gene therapy.

Products and services

Etranacogene Dezaparvovec: Adult-indicated gene therapy for severe or moderately severe Hemophilia B, offering stable steady-state efficacy and safety
LinQURE platform: Scaffold-based development platform for novel scaffolds targeting multi-transcript for the treatment of complex genetic disorders
AMT-130: Candidate-stage gene therapy for the treatment of Huntington's Disease, focusing on addressing the underlying cause of the disease

Key contacts

🔒

Financial details

🔒

1.2 - Competitors and similar companies to uniQure

Aeglea BioTherapeutics

HQ: United States Website

Description: Provider of clinical-stage enzyme therapies for rare metabolic diseases and investigational monoclonal antibody programs for IBD, including SPY001 targeting α4β7 integrin and SPY002 targeting TL1A, with rational combination studies (SPY120, SPY130, SPY230) and precision immunology approaches using genetic or biomarker-based patient selection.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full Aeglea BioTherapeutics company profile →

Castle Creek Biosciences

HQ: United States Website

Description: Provider of personalized gene therapies for rare skin and connective tissue disorders, including D-Fi (dabocemagene autoficel) for dystrophic epidermolysis bullosa using autologous genetically modified fibroblasts to express type VII collagen; an autologous fibroblast technology platform; in-house cGMP commercial-scale manufacturing; and an expanded access policy for investigational products.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full Castle Creek Biosciences company profile →

Bioniz Therapeutics

HQ: United States Website

Description: Provider of biotechnology research and drug development focused on discovering small peptides and molecules to treat autoimmune diseases and some forms of cancer, advancing proof-of-concept and preclinical studies of its lead technology and seeking partners to conduct clinical trials for regulatory approval.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full Bioniz Therapeutics company profile →

Vidara Therapeutics

HQ: United States Website

Description: Provider of specialty pharmaceutical offerings, creating value through accretive product acquisitions or license agreements, sound marketing and distribution, and life cycle management; incorporated in 2003 and based in Dublin, Ireland.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full Vidara Therapeutics company profile →

Orphan Technologies

HQ: Switzerland Website

Description: Provider of research and development of OT-58, a lead enzyme replacement therapy candidate optimized for classical homocystinuria, a genetic disease characterized by debilitating cardiovascular, skeletal, neurologic, and ophthalmologic complications.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full Orphan Technologies company profile →

🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒

🔒 View all strategic buyers with complete profiles

Start Free Trial →

2.2 - Strategic buyer groups for uniQure

🔒

Buyer group 1: ████████ ████████

●● companies

Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████

Key Products: ████████, ████████, ████████, ████████

🔒 View all companies in this group

Request Free Trial Now →

🔒

Buyer group 2: ████████ ████████

●● companies

Key Products: ████████, ████████, ████████, ████████

🔒 View all companies in this group

Request Free Trial Now →

🔒

Buyer group 3: ████████ ████████

●● companies

Key Products: ████████, ████████, ████████, ████████

🔒 View all companies in this group

Request Free Trial Now →

🔓 Unlock all detailed buyer group breakdowns with complete company profiles

Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to uniQure

Buyout Funds
50+ funds

🔒

🔒

🔒

🔒

🔒 🇺🇸 Top US buyout funds investing in uniQure's sector and industry vertical
View Funds →
🔒 🇪🇺 Top Europe buyout funds in uniQure's sector and industry vertical
View Funds →

2.2 - Growth funds investing in similar companies to uniQure

Growth Equity Funds
40+ funds

🔒

🔒

🔒

🔒

🔒 🇺🇸 Top US growth equity funds investing in uniQure's sector and industry vertical
View Funds →
🔒 🇪🇺 Top Europe growth equity funds investing in uniQure's sector and industry vertical
View Funds →

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for uniQure

4.2 - Public trading comparable groups for uniQure

🔒

Comparable group 1: ████████ ████████
●● companies

Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████

Key Metrics: Avg EV/Revenue: ●.●x, Avg Growth: ●●%

Revenue growth

Median

15.7%

2025E

16.0%

2026E

EBITDA margin

Median

28.2%

2025E

28.6%

2026E

Cash EBITDA margin

Median

27.6%

2025E

28.0%

2026E

EV/Revenue

Median

8.4x

2025E

6.8x

2026E

EV/EBITDA

Median

28.9x

2025E

24.4x

2026E

EV/Cash EBITDA

Median

29.0x

2025E

25.5x

2026E

🔒 View all companies in this group
Request Free Trial Now →

🔒

Comparable group 2: ████████ ████████
●● companies

Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████

Key Metrics: Avg EV/Revenue: ●.●x, Avg Growth: ●●%

Revenue growth

Median

15.7%

2025E

16.0%

2026E

EBITDA margin

Median

28.2%

2025E

28.6%

2026E

Cash EBITDA margin

Median

27.6%

2025E

28.0%

2026E

EV/Revenue

Median

8.4x

2025E

6.8x

2026E

EV/EBITDA

Median

28.9x

2025E

24.4x

2026E

EV/Cash EBITDA

Median

29.0x

2025E

25.5x

2026E

🔒 View all companies in this group
Request Free Trial Now →

🔒

Comparable group 3: ████████ ████████
●● companies

Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████

Key Metrics: Avg EV/Revenue: ●.●x, Avg Growth: ●●%

Revenue growth

Median

15.7%

2025E

16.0%

2026E

EBITDA margin

Median

28.2%

2025E

28.6%

2026E

Cash EBITDA margin

Median

27.6%

2025E

28.0%

2026E

EV/Revenue

Median

8.4x

2025E

6.8x

2026E

EV/EBITDA

Median

28.9x

2025E

24.4x

2026E

EV/Cash EBITDA

Median

29.0x

2025E

25.5x

2026E

🔒 View all companies in this group
Request Free Trial Now →

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to uniQure

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA

🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About uniQure

What does uniQure do?

uniQure is a provider of gene-based therapies focused on research and early development. Offerings include AMT-130 for Huntington’s disease, Etranacogene Dezaparvovec for severe or moderately severe Hemophilia B, AMT-260 for refractory temporal lobe epilepsy, AAV-miQURE targeting ALS C9orf72 transcripts, and the linQURE platform for multi-transcript targeting; a leader that developed the first and only EU-approved gene therapy.

Who are uniQure's competitors?

uniQure's competitors and similar companies include Aeglea BioTherapeutics, Castle Creek Biosciences, Bioniz Therapeutics, Vidara Therapeutics, and Orphan Technologies.

Where is uniQure headquartered?

uniQure is headquartered in The Netherlands.

How many employees does uniQure have?

uniQure has 1,000 employees 🔒.

When was uniQure founded?

uniQure was founded in 2010 🔒.

What sector and industry vertical is uniQure in?

uniQure is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for uniQure

Who are the top strategic acquirers in uniQure's sector and industry

Top strategic M&A buyers and acquirers in uniQure's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for uniQure?

Top strategic M&A buyers groups and sectors for uniQure include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in uniQure's sector and industry vertical

Which are the top PE firms investing in uniQure's sector and industry vertical?

Top PE firms investing in uniQure's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in uniQure's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in uniQure's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in uniQure's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to uniQure include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in uniQure's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for uniQure?

The key public trading comparables and valuation benchmarks for uniQure include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for uniQure for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for uniQure with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in uniQure's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for uniQure with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in uniQure's' sector and industry vertical?

Access recent funding rounds and capital raises in uniQure's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for uniQure

Start Free Trial Book a Demo